Patent Application
20220409728
The invention relates to the use of magnetic biomarkers coupled with pathogens and destruction of the pathogens through agitation of the biomarkers via an alternating magnetic field.
Pathogens are becoming harder to treat with antibiotics due to antibiotic resistant strains. Antibiotic development is on a decline as a result of the diminishing effectiveness. There exists a need for a treatment method to destroy pathogens that does not rely on antibiotics, that is safe and effective for a wide range of pathogens.
The invention is directed to the use of magnetic biomarkers coupled with pathogens and destruction of the pathogens through agitation of the biomarkers via an alternating magnetic field.
A pathogen, as used herein, is defined as bacterium, virus, or other microorganism that can cause disease.
An exemplary pathogen cell destruction method includes providing an anionic biomarker that comprises a magnetic material or a magnetic material associated or coupled thereto, such as an iron or an iron compound. The anionic biomarker is introduced into an organism having pathogen cells with a negative charge. The anionic biomarkers are attracted to the negative charges of the pathogen and couple thereto due to the electro-potential differences. The anionic biomarker may also have a coupler portion that further aids in the anionic biomarker coupling to and being bound to the pathogen cell and/or cell wall. An electric field may be produced to cause the anionic biomarkers and/or the negative charges of the pathogen cell to polarize on or along the pathogen cell. A magnetic field is directed to cause the anionic biomarker, or magnetic material thereof to move and damage the cell. The magnetic field may be an alternating magnetic field that causes the magnetic material to oscillate and damage the cell wall.
The magnetic field and the electric field may be produced at the same time or the electric field may be applied prior to the magnetic field.
An anionic biomarker may include any suitable biomarker from the FDA list of qualified biomarkers as of Jun. 18, 2021, including, but not limited to, Albumin, β2-Microglobulin, Clusterin, Cystatin C, KIM-1, Total Protein, and Trefoil factor-3, Clusterin, Renal Papillary Antigen (RPA-1), Cardiac troponins T (cTnT) and I (cTnI), Galactomannan, Fibrinogen, Total Kidney Volume (TKV), clusterin (CLU), Cystatin-C (CysC), Kidney Injury Molecule-1 (KIM-1), N-acetyl-beta-D-glucosaminidase (NAG), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and osteopontin (OPN), Plasmodium 18S rRNA/rDNA, and proteins and may have a coupler portion that has a chemical composition and/or structure to mimic a cell or molecule that the pathogen has a propensity to bond to. An anionic biomarker may include positively charged molecules, cytokines, dyes for dying bacteria, chitosan, dyes for imaging, such as CAT scan imaging.
A magnetic material that is associated or coupled with the anionic biomarker may include iron, such as iron oxide or nanoparticle of iron, such as iron oxide nanoparticles. Other ferromagnetic metals include nickel, cobalt, gadolinium, dysprosium and alloys such as steel that also contain specific ferromagnetic metals such as iron or nickel, which may be included as a compound, such as an oxide and/or a nanoparticle. Nanoparticles may be less than a micron in size and may be on the order of tens of nanometers (10 to 90 nm) to hundreds of nanometer (100 to 900 nm), such as from 10 to 500 nm, for example, or less than 750 nm, or less than about 500 nm, or even less than about 250 nm and any range between and including the nanoparticle sizes provided.
The method described herein, may be used for destroying other cells, such as cancer cells, or malignant tissue, wherein a marker is configured to be associated the cell and the marker has a magnetic material coupled thereto that can be moved or oscillated via a magnetic field. The magnetic material may be coupled with the marker initially or subsequent to the markers associating with and being configured in or around the cell or tissue.
In some embodiments, a non-oscillating magnetic field may be used to draw a magnetic material associated with a biomarker through at least a portion of a cell, such as through a portion or completely through the cell wall to destroy the cell. This method may be well suited when the biomarker and/or the magnetic material is absorbed into the cell, especially when the magnetic material is drawn into or through the cell wall.
The Aggressive Trauma Induced Alternating Magnetism system relies upon three components.
Once tagged with biomarkers and polarized by the electric current, the secondary alternating magnetic field outside the body will rapidly and repeatedly depolarize the cells and their respective biomarkers resulting in damage to the targeted cells, tissue and or pathogens.
The method provides a means to tag, or attach nontoxic biomarkers, as described herein to various bacterial, viral and oncological cells and cell structures. A pathogen cell, as used herein, may include a malignant cell, bacteria, viral, or oncological cell or portion thereof. A malignant cell may a carcinogenic pathogens such as HPV, HTLV-1, EBV, MCPyV and KSVH.
The method provides a means to polarize cells and cell structures in-vivo and to alternate the polarity of a magnetic field rapidly to destroy them.
The method provides a means to rapidly polarize and depolarize bacteria, and virus' in-vivo with the use of magnetic fields to remove flagella and surface antigens thereby making it impossible for them to attach and infect hosts.
The exemplary pathogen destruction method may work and take microbial treatment and other treatments as well in a new direction.
The summary of the invention is provided as a general introduction to some of the embodiments of the invention, and is not intended to be limiting. Additional example embodiments including variations and alternative configurations of the invention are provided herein.
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention, and together with the description serve to explain the principles of the invention.
Corresponding reference characters indicate corresponding parts throughout the several views of the figures. The figures represent an illustration of some of the embodiments of the present invention and are not to be construed as limiting the scope of the invention in any manner. Some of the figures may not show all of the features and components of the invention for ease of illustration, but it is to understood that where possible, features and components from one figure may be an included in the other figures. Further, the figures are not necessarily to scale, some features may be exaggerated to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously employ the present invention.
As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Also, use of “a” or “an” are employed to describe elements and components described herein. This is done merely for convenience and to give a general sense of the scope of the invention. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
Certain exemplary embodiments of the present invention are described herein and are illustrated in the accompanying figures. The embodiments described are only for purposes of illustrating the present invention and should not be interpreted as limiting the scope of the invention. Other embodiments of the invention, and certain modifications, combinations and improvements of the described embodiments, will occur to those skilled in the art and all such alternate embodiments, combinations, modifications, improvements are within the scope of the present invention.
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
It will be apparent to those skilled in the art that various modifications, combinations and variations can be made in the present invention without departing from the scope of the invention. Specific embodiments, features and elements described herein may be modified, and/or combined in any suitable manner. Thus, it is intended that the present invention cover the modifications, combinations and variations of this invention provided they come within the scope of the appended claims and their equivalents.
This application claims the benefit of priority to U.S. provisional patent application No. 63/215,195 filed on Jun. 25, 2021; the entirety of which is hereby incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 63215195 | Jun 2021 | US |
